OncoMatch/Clinical Trials/NCT04778839
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Is NCT04778839 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Paclitaxel and Paclitaxel Micelles for for advanced solid tumors.
Treatment: Paclitaxel · Paclitaxel Micelles for — A Phase I Study of Dose Escalation and Dose Expansion To Evaluate the Safety、Tolerability、Pharmacokinetics and Preliminary Efficacy of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumor.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: paclitaxel
Exception: unless not resistant
Patients who had been treated with paclitaxel and were determined by the researchers to be resistant
Lab requirements
Blood counts
Hb ≥ 90 g/L, ANC ≥ 1.5×10^9/L, PLT ≥ 100×10^9/L; no blood transfusion, blood products, or hematopoietic growth factors within 14 days prior to screening
Kidney function
creatinine ≤ 1.5×ULN and CL ≥ 60 mL/min
Liver function
ALT or AST ≤ 2.5×ULN (for patients with hepatic metastases, ALT or AST ≤ 5 × ULN); TBIL ≤ 1.5×ULN
Cardiac function
LVEF ≥ 50%
No severe hematopoietic abnormalities(no blood transfusion, no blood products, no granulocyte colony-stimulating factor, platelet stimulating factor, or other hematopoietic growth factors were corrected within 14 days prior to the screening phase laboratory examination):Hb≥90g/L , ANC≥1.5×109/L , PLT≥100×109/L. No serious organic disease of heart, liver or kidney:LVEF≥50% ; ALT(Alanine aminotransferase) or AST(Aspartate transaminase)≤2.5×upper limit of normal(ULN)(for patients with hepatic metastases, ALT or AST≤5 × ULN); TBIL(Total bilirubin)≤1.5×ULN; creatinine≤1.5×ULN and CL≥ 60 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify